石药(01093.HK)两款抗体药物偶联物临床试验获批

阿斯达克财经12-20 17:11

石药(01093.HK) 公布，集团所开发的抗体药物偶联物(ADC)产品SYS6043及SYS6005，均已获中国国家药品监督管理局批准，可以在中国开展临床试验。
SYS6043及SYS6005同为单克隆抗体药物偶联物，可与肿瘤表面的特异性受体结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用，均按照治疗用生物制品一类申报。

其中SYS6043获批适应症为晚期实体瘤，预计适用于治疗小细胞肺癌、食管鳞癌、头颈鳞癌、前列腺癌、肝细胞癌等。而SYS6005获批适应症是晚期肿瘤，预计适用于治疗血液肿瘤、卵巢癌、非小细胞肺癌等。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-20 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492494653?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220902171047369_s.jpg","is_english":false,"pubTime":"2024-12-20 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492494653","market":"hk","top_or_hot":-1,"title":"石药(01093.HK)两款抗体药物偶联物临床试验获批","media":"阿斯达克财经","content":"<html><body><div> <span> <p>石药(01093.HK)<span> </span>公布，集团所开发的抗体药物偶联物(ADC)产品SYS6043及SYS6005，均已获中国国家药品监督管理局批准，可以在中国开展临床试验。<br/>SYS6043及SYS6005同为单克隆抗体药物偶联物，可与肿瘤表面的特异性受体结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用，均按照治疗用生物制品一类申报。<br/><span></span><br/>其中SYS6043获批适应症为晚期实体瘤，预计适用于治疗小细胞肺癌、食管鳞癌、头颈鳞癌、前列腺癌、肝细胞癌等。而SYS6005获批适应症是晚期肿瘤，预计适用于治疗血液肿瘤、卵巢癌、非小细胞肺癌等。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-20 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药(01093.HK)两款抗体药物偶联物临床试验获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药(01093.HK)两款抗体药物偶联物临床试验获批\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-12-20 17:11</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p>石药(01093.HK)<span> </span>公布，集团所开发的抗体药物偶联物(ADC)产品SYS6043及SYS6005，均已获中国国家药品监督管理局批准，可以在中国开展临床试验。<br/>SYS6043及SYS6005同为单克隆抗体药物偶联物，可与肿瘤表面的特异性受体结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用，均按照治疗用生物制品一类申报。<br/><span></span><br/>其中SYS6043获批适应症为晚期实体瘤，预计适用于治疗小细胞肺癌、食管鳞癌、头颈鳞癌、前列腺癌、肝细胞癌等。而SYS6005获批适应症是晚期肿瘤，预计适用于治疗血液肿瘤、卵巢癌、非小细胞肺癌等。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-20 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405644/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405644/latest-news/AAFN","article_id":"2492494653","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220902171047369_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492494653","pubTimestamp":1734685860,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"石药公布，集团所开发的抗体药物偶联物产品SYS6043及SYS6005，均已获中国国家药品监督管理局批准，可以在中国开展临床试验。SYS6043及SYS6005同为单克隆抗体药物偶联物，可与肿瘤表面的特异性受体结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用，均按照治疗用生物制品一类申报。而SYS6005获批适应症是晚期肿瘤，预计适用于治疗血液肿瘤、卵巢癌、非小细胞肺癌等。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1576":"医药外包概念","BK1141":"生命科学工具和服务","01093":"石药集团","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","BK1515":"抗疫概念","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1583":"高瓴概念","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","03347":"泰格医药","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1191":"制药","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","BK1521":"挪威政府全球养老基金持仓","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC"},"translate_title":"CSPC (01093. HK) approved for clinical trials of two antibody-drug conjugates","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"01093":1},"content_text":"石药(01093.HK) 公布，集团所开发的抗体药物偶联物(ADC)产品SYS6043及SYS6005，均已获中国国家药品监督管理局批准，可以在中国开展临床试验。SYS6043及SYS6005同为单克隆抗体药物偶联物，可与肿瘤表面的特异性受体结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用，均按照治疗用生物制品一类申报。其中SYS6043获批适应症为晚期实体瘤，预计适用于治疗小细胞肺癌、食管鳞癌、头颈鳞癌、前列腺癌、肝细胞癌等。而SYS6005获批适应症是晚期肿瘤，预计适用于治疗血液肿瘤、卵巢癌、非小细胞肺癌等。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-20 16:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492494653"}